万象城AWC888

caisehengbanjiancai.png
Home
About Neukio

Corporate Overview

Development History

Corporate Culture

About Founder

Core Team
R&D

R&D Platform

Process Development
News

Press Releases
Join us

Talent Concept
Contact us
中
En
bannerd1pc-180.jpg bannerd1ph-789.jpg

Corporate News

Home
News
Press Releases
Press Releases
weixintupian_20230322095851.jpg

Neukio Biotherapeutics Reached Strategic Collaboration with Tofflon Science and Technology Group Co. Ltd to Expedite Large-scale Production of Next Generation Allogenic Cell Therapies

Press Releases

2023-03-21

See More
11-595.png

Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products

Press Releases

2022-09-02

The funds raised will play important roles in accelerating the preclinical and clinical validation of induced pluripotent stem cell (iPSC)-derived off-the-shelf CAR-NK cell therapy products, and supporting team recruitment and expansion.

See More
qianyue2(1)-442.jpg

EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies

Press Releases

2022-02-09

(February 9, 2022) EdiGene, Inc. and Neukio Biotherapeutics today announced an R&D collaboration to develop next-generation immune cell therapies.

See More
xinwen1.jpg

Neukio Biotherapeutics has completed $40m Angel round of financing and is committed to developing new NK technology platform and products

Press Releases

2021-10-25

Neukio Biotherapeutics, a newly established company, recently announced the completion of its $40m Angel round of financing led by Lilly Asia Venture (LAV), with the participation of IDG Capital and Sherpa Investments. The fund will be used mainly for th

See More
weixintupian_20230322095851.jpg

Neukio Biotherapeutics Reached Strategic Collaboration with Tofflon Science and Technology Group Co. Ltd to Expedite Large-scale Production of Next Generation Allogenic Cell Therapies

Press Releases

2023-03-21

See More
11-595.png

Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products

Press Releases

2022-09-02

The funds raised will play important roles in accelerating the preclinical and clinical validation of induced pluripotent stem cell (iPSC)-derived off-the-shelf CAR-NK cell therapy products, and supporting team recruitment and expansion.

See More
qianyue2(1)-442.jpg

EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies

Press Releases

2022-02-09

(February 9, 2022) EdiGene, Inc. and Neukio Biotherapeutics today announced an R&D collaboration to develop next-generation immune cell therapies.

See More
xinwen1.jpg

Neukio Biotherapeutics has completed $40m Angel round of financing and is committed to developing new NK technology platform and products

Press Releases

2021-10-25

Neukio Biotherapeutics, a newly established company, recently announced the completion of its $40m Angel round of financing led by Lilly Asia Venture (LAV), with the participation of IDG Capital and Sherpa Investments. The fund will be used mainly for th

See More